Analysts Anticipate Opko Health Inc. (OPK) to Post -$0.08 Earnings Per Share
Equities analysts expect Opko Health Inc. (NASDAQ:OPK) to report earnings per share of ($0.08) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.07). Opko Health posted earnings per share of ($0.12) during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Opko Health will report full-year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.17). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.34) to ($0.09). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Opko Health.
Opko Health (NASDAQ:OPK) last announced its earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The business had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. During the same quarter last year, the firm earned ($0.08) earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis.
In other news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were purchased at an average price of $5.57 per share, for a total transaction of $55,700.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 42.74% of the company’s stock.
Large investors have recently bought and sold shares of the company. ING Groep NV purchased a new stake in Opko Health in the second quarter worth approximately $1,575,000. BlackRock Inc. boosted its holdings in Opko Health by 38.7% in the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Opko Health by 842.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 106,050 shares of the biotechnology company’s stock worth $498,000 after purchasing an additional 94,799 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Opko Health by 36.5% in the second quarter. Voya Investment Management LLC now owns 124,610 shares of the biotechnology company’s stock worth $586,000 after purchasing an additional 33,289 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Opko Health by 6.1% in the second quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock worth $1,585,000 after purchasing an additional 19,316 shares during the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.
Shares of NASDAQ OPK traded down $0.28 on Wednesday, reaching $3.49. 5,445,751 shares of the company’s stock traded hands, compared to its average volume of 4,021,159. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.40. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -12.03 and a beta of 1.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.78 and a current ratio of 0.91.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Read More: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.